Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19
Clinical trial NCT05293678 · COMPLETED
Trial details
- NCT number
- NCT05293678
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-12
- Primary completion
- 2023-01-26
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.